New PET tracer could spot hidden cancers

NCT ID NCT03604315

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase I trial is testing a new radioactive tracer called [18F]FTT, which is used with PET/CT scans to find tumor cells in people with solid tumors, including breast, ovarian, and other cancers. The study will enroll 300 participants and aims to see how well the tracer highlights cancer cells compared to standard imaging. It is not a treatment but a way to improve cancer detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fluorine F 18 Fluorthanatrace ([18F]FTT)
What this could lead to
If successful, this imaging method could help doctors better detect and monitor certain cancers, like ovarian or breast cancer, by highlighting tumor cells more clearly.
What could go wrong
This is an early phase I study focused on imaging, not treatment. The tracer may not work as hoped, and results may not apply to all patients or cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.